5/13/2014 6:29:37 AM
SAN DIEGO, May 12, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, 2014. Financial highlights for the first quarter include revenues of $12.0 million and a net loss of $26.5 million, or $0.22 per share. This compares to revenues of $11.8 million and a net loss of $19.3 million, or $0.17 per share, for the first quarter of 2013. The increase in net loss reflects Halozyme's increased investment in clinical trials for its PEGPH20 and Hylenex(R) proprietary programs.
Help employers find you! Check out all the jobs and post your resume.
comments powered by